Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.49 |
| ▸ | KHK | P50053 | 2/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 10/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2214290 | 0.80 | MAPK14 (0.54) | MAPK14KHKMAPK13MAPK11 | |
| SCHEMBL2217586 | 0.78 | MAPK14 (0.59) | MAPK14MAPK13CYP3A4MAPK11 | |
| SCHEMBL4219269 | 0.76 | KHK (0.56) | MAPK14KHKMAPK13CYP2C9 | |
| SCHEMBL2216064 | 0.76 | KHK (0.56) | MAPK14KHKMAPK13CYP2C9MAPK11 | |
| SCHEMBL2216631 | 0.73 | MAPK14 (0.54) | MAPK14KHKMAPK13CYP3A4MAPK11 | |
| SCHEMBL4219336 | 0.69 | HPGDS (0.55) | MAPK14KHKMAPK13CYP2C9 | |
| SCHEMBL3429767 | 0.66 | MAPK14 (0.67) | MAPK14CYP2C9MAPK11 | |
| SCHEMBL4222804 | 0.66 | HPGDS (0.51) | MAPK14KHKMAPK13CYP2C9 | |
| SCHEMBL4220428 | 0.66 | HPGDS (0.51) | MAPK14KHKMAPK13CYP2C9 | |
| SCHEMBL4225219 | 0.66 | HPGDS (0.53) | MAPK14MAPK13CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1709046-B1 | P38 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20070161673-A1 | P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161673-A1 | P38 kinase inhibitors | MAPK1, MAPK7, MAP3K1 | MAPK14 14/4885KHK 2805/4885MAPK13 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.